Research programme: heart failure therapeutics - Cytokinetics/Amgen

Drug Profile

Research programme: heart failure therapeutics - Cytokinetics/Amgen

Alternative Names: cardiac sacromere activators; CK 0689705; CK 1122534; CK 1213296; CK 1316719; CK 689705

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytokinetics
  • Developer Amgen; Cytokinetics
  • Class Small molecules
  • Mechanism of Action Cardiac myosin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Heart failure

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Heart-failure in USA
  • 01 Mar 2015 Cytokinetics and Amgen amend agreement to extend the term of joint research programme through December 2015
  • 31 Jul 2013 Preclinical development is ongoing USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top